The treatment pipeline: new therapies are on the way.
Boyle
B A
BA
Division of International Medicine and Infectious Disease, New York Presbyterian Hospital-Weill Medical College of Cornell University, USA.
D016915:AIDS Vaccines / Q000627:therapeutic use; D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000077560:Enfuvirtide; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D063065:Organophosphonates; D010446:Peptide Fragments / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use
D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D017320:HIV Protease Inhibitors; D007376:Interleukin-2; D063065:Organophosphonates; D010446:Peptide Fragments; C105086:remune; D000077560:Enfuvirtide; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000225:Adenine; D019438:Ritonavir; C106812:adefovir dipivoxil